

Andrology Lab Corner*

Human Sperm Survival Assay as a Bioassay for the Assisted Reproductive Technologies Laboratory

CHRISTOPHER J. DE JONGE^{*}, GRACE M. CENTOLA[†], MICHAEL L. REED[‡],
ROBERT B. SHABANOWITZ[§], STEVE D. SIMON^{||} AND PATRICK QUINN[¶]

From the ^{} Reproductive Medicine Center, University of Minnesota, Minneapolis, Minnesota; [†] Andrology Laboratory, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, New York; [‡] Center for Reproductive Medicine of New Mexico, Albuquerque, New Mexico; [§] Department of Obstetrics and Gynecology, Geisinger Medical Center, Danville, Pennsylvania; ^{||} Office of Medical Research, Children's Mercy Hospital, Kansas City, Missouri; and [¶] SAGE BioPharma, San Clemente, California.*

Correspondence to: Christopher De Jonge PhD HCLD, Reproductive Medicine Center, 606 24th Avenue South, Suite 500, Minneapolis, MN 55454 (e-mail: dejonge@umn.edu).

Received for publication September 6, 2002; accepted for publication September 6, 2002.

Recently, Carrell and Cartmill ([2002](#)) provided a chronology of government oversight and intervention in the provision of clinical reproductive medicine laboratory services. They also outlined the advent and development of proficiency testing as a tool by which all clinical andrology laboratories and in vitro fertilization laboratories (herein collectively referred to as assisted reproductive technology [ART] laboratories), are able to assess themselves internally and externally. In order for ART laboratories to be deemed certified, clearly defined objectives must be met, including mechanisms for monitoring quality ([Clinical Laboratory Improvement Amendments of 1988](#)). This progression toward standardized methods for monitoring quality is not unique to the United States. The same dedication to ensuring the delivery of quality ART laboratory service and care is practiced to varying degrees throughout the world.

Rationale for Quality Control and Assurance

All products used in ART laboratories that directly or indirectly contact gametes and embryos must have no negative influence on organism viability or function ([Parinaud et al, 1987](#)). In addition, all products that directly contact gametes and embryos must be tested for toxicity before clinical implementation. In order for a laboratory to detect toxicity it must first have a reliable method for making that determination. The most appropriate mechanism for quality control/quality assurance

This Article

- ▶ [Full Text \(PDF\)](#)
- ▶ [Alert me when this article is cited](#)
- ▶ [Alert me if a correction is posted](#)

Services

- ▶ [Similar articles in this journal](#)
- ▶ [Similar articles in PubMed](#)
- ▶ [Alert me to new issues of the journal](#)
- ▶ [Download to citation manager](#)

Citing Articles

- ▶ [Citing Articles via Google Scholar](#)

Google Scholar

- ▶ [Articles by De Jonge, C. J.](#)
- ▶ [Articles by Quinn, P.](#)
- ▶ [Search for Related Content](#)

PubMed

- ▶ [PubMed Citation](#)
- ▶ [Articles by De Jonge, C. J.](#)
- ▶ [Articles by Quinn, P.](#)

(QC/QA) testing is to use a bioassay. The most appropriate bioassay is one that provides a sensitive and robust monitoring system that approximates the conditions that will be experienced by gametes and embryos during their in vitro lifetime. To ensure that the method being used performs optimally a laboratory should participate in an external proficiency-testing program.

Current Methods for QC/QA

Three bioassays are in common use for determining the acceptability of media and materials. The first and with perhaps the longest history of use is the mouse embryo assay (Ackerman et al, [1984a, b](#)). This assay involves the culture of frozen or nonfrozen, 1- or 2-cell mouse embryos to the blastocyst stage. The mouse embryo assay is easy to perform simply by virtue of the commercial availability of biological materials. However, the use of mouse embryos has several downsides, such as the reporting system for toxicity (eg, [Fleming et al, 1987](#); [Scott et al, 1993](#)), and different mouse strains vary in their sensitivity to the same test conditions ([Fleetham et al, 1993](#); [Scott et al, 1993](#)). Further, there is no apparent consensus on which mouse embryonic cell stage (eg, 1- or 2-cell) is best for use in testing ([Davidson et al, 1988](#)). There are cost issues as well, related both to the purchase of embryos on a routine basis and liquid nitrogen dewars for the storage of separate human cells and tissues. Finally, animal rights issues may also be a concern with the use of this assay.

The second most commonly used bioassay for QC and proficiency testing is the human sperm survival assay ([Critchlow et al, 1989](#); [Claassens et al, 2000](#)). This assay is convenient to perform and materials are readily available. Further, in the context of an ART laboratory, the cell type in question is familiar to testing personnel and is compatible with the clinical laboratory environment.

A less commonly used but still relevant bioassay is the hamster sperm motility assay ([Bavister and Andrews, 1988](#); [Rinehart et al, 1988](#)). This assay has a consensus in use of materials and methods alike. Similar to the mouse assay, the hamster assay can be somewhat expensive, cumbersome, and its use may also be offensive to animal rights groups.

The purpose of the present study was to determine whether the human sperm survival assay, based on the work by Claassens et al ([2000](#)), could be used effectively in a multicenter trial using a consensus protocol and whether it would yield consistent results between laboratories.

Materials and Methods

This was a multicenter (n = 5) controlled study.

Sperm Processing

Aliquots of frozen donor semen (multiple specimens from each donor) and in-house fresh specimens were tested. Fresh semen was allowed to liquefy and cryopreserved semen was allowed to thaw prior to assessing semen parameters following World Health Organization criteria ([WHO, 1999](#)). Semen was layered over a discontinuous, two-layer (47%/90% v:v) PureCeption (SAGE BioPharma, San Clemente, Calif) density gradient and centrifuged at 300 x g for 25 minutes. Sperm pellets were resuspended in 1 mL of Quinns Hepes human tubal fluid (HTF) medium (SAGE BioPharma) containing 5 mg/mL of human serum albumin (HSA) and centrifuged at 300 x g for 5 minutes. Sperm pellets were resuspended in 37° C CO₂-equilibrated bicarbonate-buffered HTF (SAGE BioPharma) and sperm parameters were assessed. Aliquots were removed and added to tubes containing HTF to achieve a

- ▲ [Top](#)
- [Materials and Methods](#)
- ▼ [Results](#)
- ▼ [Conclusions](#)
- ▼ [References](#)

final motile sperm concentration of 5×10^6 /mL. All media, including HSA, were from SAGE BioPharma.

Incubation Conditions

Sperm were incubated (0.5 mL) at 37° C in a humidified 5.0% CO₂ incubator under the following conditions: 1) HTF, 2) HTF with 5 mg/mL HSA, 3) adulterated HTF, and 4) adulterated HTF with 5 mg/mL HSA. At 2, 4, 6, 8, 24, and 48 hours aliquots were removed and added to the same volume of Hepes HTF for sperm motility assessment.

Statistical Analysis

Data were collated and analyzed using a mixed model ANOVA and linear regression. Slopes from regression lines were used for comparison. The percentage change from baseline (time = 0) was the dependent variable.

▶ **Results**

Mean motility regression lines were calculated, the slopes of which are reflective of motility change over time. For example, a slope of 0 means that motility was unchanged during the course of the experiment. A slope less than 0 means that motility decreased during the course of the experiment.

- ▲ [Top](#)
- ▲ [Materials and Methods](#)
- [Results](#)
- ▼ [Conclusions](#)
- ▼ [References](#)

Four laboratories had similar slope of motility patterns: control + HSA slope of motility > control - HSA slope of motility > treatment + HSA slope of motility > treatment - HSA slope of motility. The fifth laboratory had a slope of motility pattern as follows: control + HSA > treatment + HSA > control - HSA > treatment - HSA. The incubation conditions in laboratory 5 were not consistent (CO₂ = 6.0) with the other four laboratories, and therefore the remaining data consist of only the four laboratories that used identical incubation conditions. It is important to indicate that for control and treatment conditions, when HSA was present the regression lines for laboratory 5 were comparable to the other four laboratories.

[Table 1](#) shows the mean motility regression line slopes for the four laboratories. A negative regression line slope value reflects a decline in motility over the 48-hour incubation time. Precipitous declines in sperm motility over the 48-hour incubation time are reflected by elevated negative mean regression line slope values. When HSA was included in control and adulterated medium, the latter had a threefold steeper mean motility regression line slope compared to that of the control. When HSA was excluded from control and adulterated medium, the latter had a fivefold steeper mean motility regression line slope compared to that of the control. If the data for treatment without HSA from laboratory 1 are excluded, then the apparent difference in mean motility regression line slopes between media with or without HSA is negated.

View this table:
[\[in this window\]](#)
[\[in a new window\]](#)

Table 1. Mean motility linear regression lines per lab

[Table 2](#) reflects the mean regression values for the same donor tested at different laboratory locations. These data are consistent with those in [Table 1](#), in which mean regression line slope

values are greater (reflective of a more precipitous rate of decline in motility) for sperm incubated in adulterated medium compared with sperm incubated in control medium. In addition, there appears to be greater sensitivity to the adulterant, as indicated by the regression line slope values, when HSA is excluded from the medium. There is also an apparent greater variation in the rate at which sperm lost motility under these conditions as suggested by the large standard deviations.

View this table: [Table 2. Mean motility linear regression lines per cryopreserved donor specimen](#)
[\[in this window\]](#)
[\[in a new window\]](#)

▶ **Conclusions**

The present data concur with those published by Claassens et al (2000) in that sperm motility is influenced by the presence or absence of protein in incubation medium adulterated by a potential toxicant. In order to more readily interpret the data in our study, mean regression lines were calculated, the slope of which is reflective of an increase, a decrease, or no change in sperm motility over time. In the present study a deleterious effect by adulterant on sperm motility was detected, as evidenced by negative slope of regression line values < -1 , regardless of whether or not the media contained protein. In contrast, sperm motility changed only minimally after incubation in nonadulterated media and regardless of whether or not protein was added. Motility appeared to be more negatively influenced when the medium contained adulterant and lacked protein, suggesting a possible protective effect by protein on sperm from cytotoxic substances in the test media. However, more testing is required to validate this hypothesis.

- ▲ [Top](#)
- ▲ [Materials and Methods](#)
- ▲ [Results](#)
- [Conclusions](#)
- ▼ [References](#)

Quality control and proficiency testing for ART laboratories has historically been problematic. The commonly used mouse embryo assay suffers from strain dependence, high cost, and other negative factors. As demonstrated by the results herein, the sperm survival assay, when performed under controlled conditions, can be used effectively as part of standard quality monitoring and proficiency testing programs. The inherent problems found with use of other bioassays currently in use are minimized or eliminated with the use of the human sperm survival assay.

The human sperm survival assay performs well as a bioassay for testing gamete toxicity by contact materials, reagents, and media, which are essential for ART laboratories. However, it is important to caution that the sensitivity of the sperm survival assay remains to be established. These results also show that performance data from the sperm survival assay between different laboratories is comparable, and thus can be not only compared, but used in proficiency testing regimens, and other inter-laboratory tests of competence.

▶ **Footnotes**

* *Andrology Lab Corner* welcomes the submission of unsolicited manuscripts, requested reviews, and articles in a debate format. Manuscripts will be reviewed and edited by the Section Editor. Papers appearing in this section are not considered primary research reports and are thus not subjected to

peer review. All submissions should be sent to the *Journal of Andrology* Editorial Offices. Letters to the editor in response to articles as well as suggested topics for future issues are encouraged. [+](#)

References

- [▲ Top](#)
- [▲ Materials and Methods](#)
- [▲ Results](#)
- [▲ Conclusions](#)
- [References](#)

Ackerman SB, Swanson RJ, Stokes GK, Veeck LL. Culture of mouse preimplantation embryos as a quality control assay for human in vitro fertilization. *Gamete Res.* 1984a; 9:145 -152.

Ackerman SB, Taylor SP, Swanson RJ, Laurell LH. Mouse embryo culture for screening in human IVF. *Arch Androl.* 1984b; 12(suppl):129 -136.

Bavister BD, Andrews JC. A rapid sperm motility bioassay procedure for quality-control testing of water and culture media. *J IVFET.* 1988;5:67 -75.

Carrell DT, Cartmill D. A brief review of current and proposed federal government regulation of assisted reproduction laboratories in the United States. *J Androl.* 2002; 23:611 -617. [\[Free Full Text\]](#)

Claassens OE, Wehr JB, Harrison KL. Optimizing sensitivity of the human sperm motility assay for embryo toxicity testing. *Hum Reprod.* 2000;15:1586 -1591. [\[Abstract/Free Full Text\]](#)

Clinical Laboratory Improvement Amendments of 1988: Final Rule, *57Federal Register* 7002 (1992).

Critchlow JD, Matson PL, Newman MC, Horne G, Troup SA, Lieberman BA. Quality control in an in-vitro fertilization laboratory: use of human sperm survival studies. *Hum Reprod.* 1989; 4:545 -549. [\[Abstract/Free Full Text\]](#)

Davidson A, Vermesh M, Lobo RA, Paulson RJ. Mouse embryo culture as quality control for human in vitro fertilization: the one-cell versus the two-cell model. *Fertil Steril.* 1988; 49:516 -521. [\[Medline\]](#)

Fleetham JA, Pattinson HA, Mortimer D. The mouse embryo culture system: improving the sensitivity for use as a quality control assay for human in vitro fertilization. *Fertil Steril.* 1993; 59:192 -196. [\[Medline\]](#)

Fleming TP, Pratt HPM, Braude PR. The use of mouse preimplantation embryos for quality control of culture reagents in human in vitro fertilization programs: a cautionary note. *Fertil Steril.* 1987;47:858 -860. [\[Medline\]](#)

Parinaud J, Reme J-M, Monrozier X, Favrin S, Sarramon M-F, Pontonnier G. Mouse system quality control is necessary before the use of new material for in vitro fertilization and embryo transfer. *J IVFET.* 1987;4:56 -58.

Rinehart JS, Bavister BD, Gerrity M. Quality control in the in vitro fertilization laboratory: comparison of bioassay systems for water quality. *J IVFET.* 1988; 5:335 -342.

Scott LF, Sundaram SG, Smith S. The relevance and use of mouse embryo bioassays for quality control in an assisted reproductive technology program. *Fertil Steril.* 1993; 60:559 -568. [\[Medline\]](#)

World Health Organization. *WHO Laboratory Manual for the Examination of Human Semen and Sperm—Cervical Mucus Interaction.* Cambridge: Cambridge University Press; 1999 .

This Article

- ▶ [Full Text \(PDF\)](#)
- ▶ [Alert me when this article is cited](#)
- ▶ [Alert me if a correction is posted](#)

Services

- ▶ [Similar articles in this journal](#)
- ▶ [Similar articles in PubMed](#)
- ▶ [Alert me to new issues of the journal](#)
- ▶ [Download to citation manager](#)

Citing Articles

- ▶ [Citing Articles via Google Scholar](#)

Google Scholar

- ▶ [Articles by De Jonge, C. J.](#)
- ▶ [Articles by Quinn, P.](#)
- ▶ [Search for Related Content](#)

PubMed

- ▶ [PubMed Citation](#)
- ▶ [Articles by De Jonge, C. J.](#)
- ▶ [Articles by Quinn, P.](#)